Skip to content
    Compare notes on r/BodyHackGuideCompare notes with other researchers. Join r/BodyHackGuide

    ITPP

    Performance

    Status
    Preclinical, , not approved for human use
    Evidence

    Small human trials, none in exercise, graded on the Endurance Stack

    ITPP (myo-inositol trispyrophosphate, sometimes written myo-inositol tripyrophosphate or OXY111A in NormOxys trial documents) is a small-molecule allosteric effector of hemoglobin designed to increase the amount of oxygen red blood cells release to tissues.

    Reviewed

    01Overview

    What ITPP is

    It was developed in the mid-2000s by Claude Nicolau and collaborators working out of Tufts University and the French biotech NormOxys, with the stated goal of creating an oral or injectable drug that could mimic what the body's own 2,3-bisphosphoglycerate (2,3-BPG) does inside red blood cells — only longer-acting and more potent. The molecule was designed by phosphorylating the inositol ring until it carried six phosphate groups arranged as three pyrophosphate units, giving it a negative charge density high enough to penetrate the erythrocyte membrane and bind the central cavity of hemoglobin at the same allosteric site 2,3-BPG uses.

    Read the full overviewShow less

    ITPP is classified as a right-shifter of the oxygen–hemoglobin dissociation curve. In plain language, that means a hemoglobin molecule carrying ITPP lets go of its oxygen more easily than hemoglobin alone. Under ordinary conditions, that is a problem — oxygen dropping off too early would starve the brain and cardiac muscle — but in specific pathological states where tissue is hypoxic (cancerous tumors, ischemic heart muscle, sickled erythrocytes, emphysematous lung), the extra unloading pressure can push oxygen into compartments that were previously starved. Preclinical and early clinical work has focused on exactly those states.

    In the research body-hacking community, ITPP entered the conversation because of its theoretical endurance-improving properties — the same thing that made it attractive as a heart-failure drug made it attractive to dopers. It became notorious around 2011–2013 after French racehorse trainers were accused of injecting thoroughbreds with ITPP to extend their aerobic capacity; the horse-doping story accelerated the compound's visibility and also shifted how regulators catalogued it. The World Anti-Doping Agency does not name ITPP on its Prohibited List, including the 2026 edition. What that List prohibits at all times is the method M1.2, artificially enhancing the uptake, transport or delivery of oxygen, whose named examples are perfluorochemicals, efaproxiral (RSR13), voxelotor and modified haemoglobin products. Horse racing prohibits ITPP by name, and validated assays exist for human urine and equine plasma (PMID: 25070041, PMID: 38924320). If you are a tested athlete, assume ITPP will cost you your career.

    This entry takes the position that ITPP is a research compound with intriguing preclinical data, zero human safety record outside small company-sponsored trials, no approved medical indication, and a banned-substance designation in sport. It covers mechanism, the small amount of real human data that exists, the doping chapter, practical considerations for readers who insist on engaging with it, and the overwhelming reasons most people should leave it alone. For related oxygen-delivery–adjacent interventions, see EPO and tissue-protective fragments, mitochondrial uncouplers, and metabolic exercise mimetics.

    How it works

    The mechanism of ITPP is elegant and narrow. Hemoglobin inside a red blood cell exists in equilibrium between a high-oxygen-affinity R-state (relaxed, binds O2 tightly) and a low-oxygen-affinity T-state (tense, releases O2). Under normal physiology, a small molecule called 2,3-bisphosphoglycerate (2,3-BPG) sits in the central cavity of hemoglobin and stabilizes the T-state. That is why red blood cells with high 2,3-BPG concentrations — such as those generated during altitude acclimatization — offload more oxygen at a given partial pressure than cells with low 2,3-BPG.

    Read the full mechanismShow less

    ITPP was engineered specifically to mimic and exceed 2,3-BPG's stabilization of the T-state. Its six phosphate groups give it a charge profile even more negative than 2,3-BPG, and it binds the same central cavity with higher avidity. Once inside the red blood cell and bound to hemoglobin, ITPP forces a measurable right-shift of the oxygen dissociation curve — typically quantified as an increase in P50, the partial pressure of oxygen at which hemoglobin is 50% saturated. A higher P50 means hemoglobin needs a higher PO2 to stay saturated, which is another way of saying oxygen drops off sooner as blood passes through tissue.

    The critical question is how ITPP crosses the red blood cell membrane. Free 2,3-BPG cannot cross it at all — red cells make their own internally. ITPP is believed to cross via a combination of passive diffusion across perturbed membranes in oxidatively stressed cells and facilitated entry under conditions of hypoxia. Once inside, it is not efficiently effluxed, so the effect persists for the lifespan of the red blood cell carrying it (weeks, in theory). In practice, pharmacokinetic modeling from the [Biolo et al. 2009 preclinical work] and [Kieda et al. 2013 tumor oxygenation study] suggests the right-shift in P50 after a single IV dose persists for several days and progressively declines as unmodified red cells are replaced.

    Downstream consequences extend beyond simple oxygen delivery. Multiple groups have reported that ITPP-treated animals show:

    • Reduced tumor hypoxia (measured by pimonidazole staining, HIF-1α reduction), which in principle re-sensitizes tumors to radiotherapy and oxygen-dependent chemotherapy
    • Improved cardiac function in failing hearts (Biolo 2009 — ITPP restored exercise tolerance in a rat congestive heart failure model)
    • Attenuation of tumor metastasis in murine melanoma and pancreatic cancer models, hypothesized to occur via normalization of the hypoxic tumor niche that drives invasive phenotypes
    • Potential benefit in sickle cell disease via destabilization of HbS polymer formation (preclinical only)

    The mechanism is not erythropoietin-like. ITPP does not increase red cell count or hemoglobin concentration. It changes the behavior of existing hemoglobin. That distinction matters both pharmacologically and from an anti-doping detection standpoint — ITPP is detectable on specific assays that target inositol pyrophosphate signatures, not by the hemoglobin-count tests used to catch EPO abuse.

    Benefits listed

    • Enhanced tissue oxygenation
    • Improved aerobic performance
    • Anti-tumor effects (reduces tumor hypoxia)
    • Potential altitude sickness relief
    Show 1 moreShow less
    • Improved exercise capacity

    02Research

    Free with email

    What the research shows

    Graded on a research bench

    Reference pages that put ITPP next to the compounds people pair it with: roles, evidence, overlap and conflicts. No dosing. Research use only.

    Unlock the research summary

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • A summary of the key research
    • Safety and side effects
    • A link to the PubMed results

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    03Safety

    ITPP side effects and interactions

    Side effects

    Not in our record

    Our record lists no side effects for ITPP. That means none are recorded here, not that there are none. The Research section has the written safety notes.

    Who should not use it

    Contraindications

    Absolute contraindications:

    • Pregnancy and lactation — no reproductive or developmental toxicity data in humans
    • Chronic kidney disease stage 3 or higher — phosphate handling impaired; risk of hyperphosphatemia and secondary hyperparathyroidism
    • Primary lung disease with reduced diffusion capacity — right-shifting O2 curve impairs pulmonary oxygen uptake
    • Active sickle cell crisis outside supervised protocol
    • Current hematologic malignancy outside registered trial
    • Active thrombotic disease or high-risk thrombotic state
    • Known hypersensitivity to ITPP or related inositol phosphate derivatives
    • Participation in any tested sport or event subject to WADA or equivalent anti-doping jurisdiction
    • Pediatric use — zero data in humans under 18
    • Any user without access to IV-capable clinical monitoring for advanced protocols
    Read all the contraindications and cautionsShow less

    Relative contraindications requiring medical oversight:

    • Chronic heart failure outside monitored protocol
    • Chronic kidney disease stage 2
    • Any active electrolyte disturbance, especially calcium or phosphate
    • Recent myocardial infarction or unstable angina
    • Recent stroke or TIA
    • Severe anemia of any cause
    • Liver disease with elevated enzymes or synthetic dysfunction
    • Concurrent high-dose stimulant or sympathomimetic use
    • Concurrent EPO, darbepoetin, or other erythropoiesis-stimulating agents
    • Any history of pulmonary embolism or deep vein thrombosis
    • Concurrent use of anticoagulants or antiplatelet agents without specialist oversight
    • High-altitude residence or planned altitude exposure during dosing cycle

    Drug interactions to evaluate:

    • Loop diuretics — additive calcium loss risk given phosphate load
    • Phosphate binders — will reduce systemic ITPP exposure if oral
    • Bisphosphonates — theoretical interaction on bone mineral metabolism
    • Statins — no known direct interaction but monitor liver function
    • Concurrent chemotherapy — effect on specific agents' pharmacokinetics not characterized for most cytotoxics
    • Other erythrocyte-modifying compounds — additive or unpredictable effects

    Populations where ITPP should be approached only inside a registered clinical trial:

    • Advanced cancer patients interested in hypoxia-modifying therapy
    • Sickle cell disease research participants
    • Advanced heart failure patients in investigational protocols

    Monitoring baseline before any protocol:

    • CBC with differential
    • Comprehensive metabolic panel including calcium, phosphate, magnesium, and ionized calcium if available
    • Renal function — creatinine, BUN, eGFR, urinalysis
    • Liver function — AST, ALT, ALP, bilirubin, albumin
    • Coagulation — PT, INR, aPTT, and D-dimer if clinically indicated
    • Cardiac — ECG; echocardiogram if any cardiac history
    • Pulmonary — pulse oximetry at rest; consider DLCO if any pulmonary symptoms
    • Iron studies — ferritin, transferrin saturation, to contextualize any oxygen-delivery intervention
    • Hemoglobin A1c and fasting glucose for metabolic baseline
    • Thyroid panel if dose-escalating

    Drug testing: if you are subject to any anti-doping testing, ITPP use is disqualifying. Specific inositol phosphate assays in current WADA labs detect ITPP with multi-week analytical windows.

    If any of these contraindications apply, the correct protocol is to not use ITPP and to investigate alternative oxygen-delivery optimization through altitude training, iron and ferritin optimization, legitimate mitochondrial support stacks, and structured aerobic periodization.

    Interactions

    2 pairings in our record: 1 with a caution and 1 noted as compatible or synergistic. Compatible and synergistic are notes from the record, not safety findings.

    • EPO

      Caution

      Both affect oxygen delivery — risk of polycythemia if combining

    • SLU-PP-332

      Compatible

      ITPP for oxygenation + SLU-PP-332 for exercise mimicry — complementary performance enhancement

    This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

    Order Bloodwork

    04Dosing

    Free with email

    ITPP dosage and protocols

    Dose range
    Research compound — IV infusion in studies, no established oral doses

    Unlock the dosing protocols

    Enter your email to keep reading. It is free, and it opens these sections on every compound page in this browser.

    • Beginner, intermediate and advanced protocols
    • Reconstitution and handling notes
    • Stacking notes
    • Additional dosage notes

    You also get the free peptide cheat sheet by email. Unsubscribe anytime.

    Have an account? Sign in

    05Prices

    ITPP prices

    1 listing from 1 vendor, opening in the Featured order.

    Pack prices
    $139.99
    Lowest per mg
    $0.035/mg
    Vendors
    1
    Listings
    1 (liquid)

    Prices as the vendors list them, last recorded 27 October 2026.

    Form
    Sort
    ITPP listings, in Featured order
    VendorProductPriceBuy

    ITPP 200 mg/mL

    liquid, 20 mL (200 mg/mL)

    Out of stock

    $0.035/mg

    $139.99

    View ITPP 200 mg/mL at Disguised Alpha
    Vendors selling ITPP(1: trust score, certificates, payment, shipping)

    Every supplier above is graded 0 to 100 on COA verification, payment transparency, shipping, reviews, and active listings. Methodology published, no pay-to-rank. How we score these vendors

    Price history(2 days with a recorded price)
    Review ITPP

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with ITPP.

    06Chemistry

    Chemistry and structure

    Molecular formula
    C6H12O21P6
    Molecular mass
    605.99 g/mol
    CAS number
    802590-64-3
    IUPAC name
    myo-Inositol trispyrophosphate
    View on PubChem

    08Questions

    Frequently asked questions

    Is ITPP legal?

    ITPP's legal status depends on jurisdiction and use. It is not an FDA-approved drug in the United States, it is not approved by the EMA in Europe, and it has no consumer marketing authorization anywhere. In most jurisdictions it can be legally possessed for laboratory research but cannot be legally sold or administered as a human therapeutic outside of a registered clinical trial. It is on the WADA prohibited list for tested athletes in all sanctioned sport. Horse racing regulators treat it as a doping violation. Readers should consult local counsel and never use it in tested sport. For a legal, research-grade alternative in the exercise-mimetic space, see SLU-PP-915.

    What does ITPP actually do?

    ITPP is an allosteric effector of hemoglobin. It binds the central cavity of hemoglobin at the same site as the body's natural 2,3-BPG but with higher potency, shifting the oxygen-hemoglobin dissociation curve to the right. In plain language: red blood cells release more of their oxygen to tissue at a given partial pressure. That is useful in contexts where tissue is hypoxic — tumors, ischemic myocardium, sickled red cells — and is the mechanism behind its experimental use in advanced cancer and heart failure trials.

    Is ITPP the same as EPO?

    No. EPO increases the number of red blood cells by stimulating bone marrow erythropoiesis. ITPP does not change red blood cell count. Instead, it changes how existing hemoglobin behaves by shifting the P50 rightward. The two mechanisms are complementary on paper but are different pharmacologies, are detected by different anti-doping assays, and have very different safety profiles. For readers interested in tissue protection rather than oxygen-carrying capacity, the EPO-related tissue-protective fragment ARA-290 occupies a different mechanistic niche.

    Can ITPP improve my endurance for training?

    There is no ethical way to answer 'yes' for any reader subject to tested sport. ITPP is banned under WADA and most equivalent bodies. Use in tested competition is a positive test with career-ending consequences. For untested recreational training, the animal and limited human data suggest the mechanism should translate to some performance benefit, but there are no peer-reviewed endurance RCTs in healthy humans to quantify how much benefit, how durable, or at what safety cost. The more honest answer for nearly all readers is: pursue endurance gains through altitude work, iron optimization, structured training, and legitimate exercise-mimetic pharmacology like SLU-PP-915.

    Is ITPP dangerous?

    It carries real risks that are not fully characterized in humans. Known risks include paresthesias, hypotension, calcium and phosphate shifts, and elevated liver and renal markers. Theoretical risks include thrombotic events, pulmonary oxygenation impairment at high doses, and unknown chronic-exposure effects. Compared with most supplements, ITPP sits firmly in the investigational-pharmaceutical risk tier — comparable to oncology chemotherapy in terms of monitoring requirements. Home-setting self-administration is not a defensible posture.

    How long do ITPP effects last after a dose?

    A single IV dose produces a measurable right-shift in P50 that persists for 24–72 hours with full magnitude and then gradually declines over 5–7 days as the modified red blood cell population is diluted by fresh erythrocytes. Multiple doses per week are used in oncology protocols to maintain sustained oxygen-offloading effect. The detection window for anti-doping testing is substantially longer — weeks — because inositol polyphosphate signatures persist at detectable levels after the functional pharmacologic effect has faded.

    Does ITPP affect my resting oxygen saturation?

    At typical doses, pulse oximetry readings remain within normal range. What changes is the distribution of oxygen between blood and tissue, not the total amount. In principle, at very high doses or in patients with pulmonary disease, the right-shift can begin to impair pulmonary oxygen uptake and show up as desaturation on SpO2. This is one of the key monitoring parameters during administration.

    Why was ITPP used in horse racing?

    The mechanism — sustained increase in peripheral oxygen delivery without changing red blood cell count — made ITPP attractive as a doping agent for endurance-intensive racing. Between 2011 and 2013, multiple thoroughbred racing jurisdictions including France, Australia, and the United States reported positive tests. The scandal accelerated development of specific anti-doping assays for inositol polyphosphates and precipitated ITPP's formal addition to the WADA prohibited list. Equine use remains a live enforcement issue and any ITPP detection in a tested horse or human results in sanctions.

    What's the difference between ITPP and altitude training?

    Altitude training gradually increases the body's own 2,3-BPG production and can also stimulate erythropoiesis, producing durable, physiologic, non-banned improvements in oxygen delivery over weeks to months. ITPP bypasses the physiology and chemically forces a larger right-shift in hours, without changing 2,3-BPG or red cell count. Altitude is legal, safe when properly periodized, and has decades of sport-science literature. ITPP is faster-acting but banned, poorly characterized, and risky. For nearly all readers, altitude and hypoxic tent protocols are the correct path — see stack and protocol resources.

    If I can't use ITPP, what should I actually do for oxygen delivery and endurance?

    Start with the fundamentals that are legal in tested sport, well-characterized, and compoundable. First: verify iron and ferritin status with labs and repair deficits with diet or iron supplementation under medical guidance. Second: implement a periodized aerobic training plan with appropriate intensity distribution. Third: consider altitude exposure (live-high or sleep-high protocols) or intermittent hypoxic training. Fourth: layer in mitochondrial support from L-carnitine, CoQ10, and NAD+ precursors where clinically reasonable. Fifth: if research-grade exercise-mimetic pharmacology is within your risk tolerance and jurisdiction, SLU-PP-915 and 5-Amino-1MQ are more evidence-aligned entry points than ITPP. The combination of these strategies, executed consistently over months, will produce endurance improvements that are durable, legal, and unlikely to cost you your career or your health.

    How many vendors sell ITPP, and what does it cost per mg?

    1 of the vendors BodyHackGuide tracks list ITPP (1 listing). The lowest listed price BodyHackGuide has recorded for ITPP is $139.99. No ITPP listing recorded as in stock carries a milligram count, so BodyHackGuide states no price per milligram for ITPP.

    Which vendors have third-party COAs for ITPP on file at BodyHackGuide?

    BodyHackGuide holds no third-party certificate records for ITPP. Each vendor page on BodyHackGuide shows how many certificate records BodyHackGuide holds for that vendor.

    Free 2026 Peptide Cheat Sheet (PDF)

    38 compounds and blends: vial sizes, BAC water volumes, dosing ranges and bloodwork markers.

    Download Free